MicroRNA-155 has been implicated in several autoimmune diseases, including experimental autoimmune encephalomyelitis and rheumatoid arthritis, due to its activity against a wide range of immunological gene targets. Overexpression of miR-155 may represent a hallmark feature in Alopecia areata (AA) disease pathogenesis and across multiple autoimmune conditions. It could potentially reflect and or influence the activation of T cells in autoimmune diseas. The present work aims is to assess serum level of miRNA-155 in patients with AA. MiR-155 level was identified by real-time polymerase chain reaction (PCR) in 30 patients with AA and 30 individuals as healthy controls. Results: There was a statistically significant increase in serum miR-155 level in patients than in controls. Conclusion: Serum level of miR-155 was significantly higher in patients with AA than controls, which indicated its role in the pathogenesis of AA.
Sorour, N., Hamed, A., Tabl, H., & Mousa, S. (2018). Serum MicroRNA-155 Expression Level as a Novel Biomarker in Alopecia Areata Patients. Benha Journal of Applied Sciences, 3(2), 105-106. doi: 10.21608/bjas.2018.191356
MLA
N.E. Sorour; A.H. Hamed; H.A. Tabl; SH.G. Mousa. "Serum MicroRNA-155 Expression Level as a Novel Biomarker in Alopecia Areata Patients", Benha Journal of Applied Sciences, 3, 2, 2018, 105-106. doi: 10.21608/bjas.2018.191356
HARVARD
Sorour, N., Hamed, A., Tabl, H., Mousa, S. (2018). 'Serum MicroRNA-155 Expression Level as a Novel Biomarker in Alopecia Areata Patients', Benha Journal of Applied Sciences, 3(2), pp. 105-106. doi: 10.21608/bjas.2018.191356
VANCOUVER
Sorour, N., Hamed, A., Tabl, H., Mousa, S. Serum MicroRNA-155 Expression Level as a Novel Biomarker in Alopecia Areata Patients. Benha Journal of Applied Sciences, 2018; 3(2): 105-106. doi: 10.21608/bjas.2018.191356
)
View on SCiNiTO